- LON: SNG is trading more than 10% higher, above 210 pence after its coronavirus cure proved efficient.
- Synairgen PLC's CEO Richard Marsen said that "things are moving very quickly."
- The pharma firm's collaboration with larger companies may scale up production.
LON: SNG was trading at around 35 pence per share only on Friday and is now around 210 pence – around six times its value. Synairgen PLC's stock is rising by over 10% on Tuesday, extending its surge recorded on Monday following the announcement that its drug drastically improves the survival chances of COVID-19 patients and helps them avoid complications – a 79% difference.
Richard Marsden, Chief Executive Officer of Synairgen, told Bloomberg TV that "things are moving very quickly" when referring to receiving approval for wide approval of the drug. British authorities have been eager to throw money at any vaccine or cure and have also been willing to fast-track of approvals. Other countries will likely follow the UK in giving a green light for usage if London does so.
Moreover, Marsden said that he is in touch with several larger pharmaceutical companies regarding scaling up the production of the medication. While the large firms may take a cut from SNG's profits, the rapid distribution could help it gain market share. It could also open the door to one of the giants purchasing the Synargien, which is only valued at around £328 million. That seems like a modest sum for a company at the forefront of the worst medical disaster in recent history.
Synairgen Stock Price
LON: SNG has already hit a high of 240 pence, and may be experiencing some profit-taking. Any upbeat news may push it higher. The round 200 pence level serves as a battleground.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD holds above 0.6500 in thin trading
The Australian Dollar managed to recover ground against its American rival after AUD/USD fell to 0.6484. The upbeat tone of Wall Street underpinned the Aussie despite broad US Dollar strength and tepid Australian data.
EUR/USD comfortable below 1.0800 lower lows at sight
The EUR/USD pair lost ground on Thursday and settled near a fresh March low of 1.0774. Strong US data and hawkish Fed speakers comments lead the way ahead of the release of the US PCE Price Index on Friday.
Gold pulls away from daily highs, holds above $2,200
Gold retreats from daily highs but holds comfortably above $2,200 in the American session on Thursday. The benchmark 10-year US Treasury bond yield stays near 4.2% after upbeat US data and makes it difficult for XAU/USD to gather further bullish momentum.
Google starts indexing Bitcoin addresses
Bitcoin address data is live on Google search results after users realized on Thursday that the tech giant started indexing Bitcoin blockchain data. However, mixed reactions have followed the tech giant's reversed stance on the cryptocurrency.
A Hollywood ending for fourth quarter GDP
The latest revisions put Q4 GDP at 3.4%, the second fastest quarterly growth rate in two years. Much of the upside was attributable to stronger consumer spending, yet fresh profits data affirmed it was a good quarter for the bottom line as well with profits up by the most since the Q2-2022.